- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03591068
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado SOM, Department of Otolaryngology
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas Health Science Center at Houston, McGovern Medical School, Dept. of Otolaryngology, Head and Neck Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women aged 18 years and older at Visit 1 (Baseline/Day1)
Women of child bearing potential must be abstinent, or if sexually active,
- be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
- be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
- be postmenopausal (amenorrhea for at least 1 year).
- Women of child-bearing potential must have a negative urine pregnancy test at Visit 1 (Day 1/Baseline)
- Must have bilateral nasal polyposis with a grade of 2 or 3 in at least one side of the nasal cavity as determined by a nasal polyp grading scale score measured by nasoendoscopy at Visit 1 (Day 1/Baseline)
- Must have a SNOT-22 score of ≥20 at Visit 1(Baseline/Day 1)
- Must have been on an adequate dose of an intranasal corticosteroid (e.g. fluticasone propionate, fluticasone furoate, mometasone, triamcinolone, ciclosenide, budesonide, budesonide respules, beclomethasone) for at least 1 month, in the previous 3 months prior to Visit 1 (Day 1/Baseline)
- Subjects with comorbid asthma or chronic obstructive pulmonary disease (COPD) must be stable with no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral steroid use) within the 3 months before the screening visit. Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent) for at least 3 months before screening with plans to continue use throughout the study
- Must be able to cease treatment with oral steroids, intranasal steroids, inhaled corticosteroids (except permitted doses listed above for asthma and COPD) at Visit 1 (Day 1/Baseline)
- Must demonstrate correct use of the demo EDS
- Ability to read and speak English
- Must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
Exclusion Criteria:
- Women who are pregnant or lactating
- Inability to have each nasal cavity examined for any reason, including nasal septum deviation
- Have used XHANCE™ (fluticasone propionate) nasal spray within the past 2 months
- Nasal septum perforation
- Has had more than 1 episode of epistaxis with frank bleeding in the month before Visit 1 (Day 1/Baseline)
- Have evidence of significant mucosal injury or ulceration (e.g. exposed cartilage) on Visit 1 (Day 1/Baseline) nasal examination/nasoendoscopy
- History of sinus or nasal surgery within 3 months before Visit 1 (Day 1/Baseline). If >3 months subject should be fully recovered from surgery
- Current, ongoing rhinitis medicamentosa (rebound rhinitis)
- Have significant oral structural abnormalities, e.g., a cleft palate
- Diagnosis of cystic fibrosis
- History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
- Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within 2 weeks before Visit 1 (Day 1/Baseline). Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution
- Planned sinonasal surgery during the period of the study
- Allergy, hypersensitivity, or contraindication to corticosteroids, steroids, or to any excipients in OPN-375
- Exposure to any glucocorticoid treatment with potential for systemic effects (e.g., oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before Visit 1 (Day 1/Baseline); except as noted in inclusion criteria for subjects with comorbid asthma or COPD
- Have nasal candidiasis at Visit 1 (Day 1/Baseline)
- History or current diagnosis of any form of glaucoma, ocular hypertension, or intraocular pressure elevation on any form of steroid therapy
- History or current diagnosis of the presence (in either eye) of a sub-capsular cataract
- Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
- Recent (within 1 year of Visit 1 (Day 1/Baseline)) history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study
- Have participated in an investigational drug clinical trial within 30 days of Visit 1 (Day 1/Baseline)
- Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: OPN-375 186 mcg BID
|
OPN-375 186 μg BID, Delivered via exhalation delivery system
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video
Time Frame: Week 24
|
: Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment for Safety by Recording Adverse Events and Adverse Events of Special Interests
Time Frame: 24 Weeks, up to 30 days after last dose
|
24 Weeks, up to 30 days after last dose
|
|
Assessment for Safety Through Nasal Examination
Time Frame: 24 Weeks, up to 30 days after last dose
|
Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum.
If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma
|
24 Weeks, up to 30 days after last dose
|
Assessment for Safety From Recording Vital Sign - Blood Pressure
Time Frame: Baseline, Week 12, Week 24
|
Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)
|
Baseline, Week 12, Week 24
|
Assessment for Safety From Recording Vital Sign - Pulse
Time Frame: Baseline, Week 12, Week 24
|
measure pulse in beats per minute (bpm)
|
Baseline, Week 12, Week 24
|
Assessment for Safety From the Collection of Information for Concomitant Medications Usage
Time Frame: 24 Weeks, up to 30 days after last dose
|
24 Weeks, up to 30 days after last dose
|
|
Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities)
Time Frame: Week 24
|
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps
|
Week 24
|
Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade
Time Frame: Week 24
|
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps
|
Week 24
|
Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit
Time Frame: Week 24
|
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps
|
Week 24
|
Sinonasal Outcome Test 22 (SNOT-22) Total Score
Time Frame: Week 24
|
SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem
|
Week 24
|
Sniffin' Sticks N-butanol Test
Time Frame: Week 24
|
The Sniffin' Sticks n-butanol (Extended test) are used to investigate human olfactory performance by use of odor pens.
the Extended Test consists of 3 different subtests: Threshold, Discrimination and Identification.
the Threshold test is used to ascertain the patient's olfactory threshold.
the Discrimination test requires the patient to differentiate smells.
The Identification test requires the patient to identify everyday smells by means of a card with different choices.
The result of this test is expressed as the sum of the results of the 3 subtests, the so called TDI score (threshold, discrimination, identification).
A score of more than 30 rates as normal, a score of 30 or less indicates hyposmia and a score of 15 and below point to functional anosmia in form of complete loss of the sense of smell or an extremely weakened smell ability.
|
Week 24
|
Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved
Time Frame: Week 24
|
The Patient Global Impression of Change (PGIC), is a questionnaire where the patient rates the change in their symptoms.
Score range is from 1 (very much improved) to 7 (very much worse)
|
Week 24
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Pathological Conditions, Anatomical
- Nose Diseases
- Polyps
- Nasal Polyps
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Fluticasone
- Xhance
Other Study ID Numbers
- OPN-FLU-NP-3104
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasal Polyposis
-
Optinose US Inc.CompletedBilateral Nasal PolyposisUnited States
-
Idorsia Pharmaceuticals Ltd.CompletedBilateral Nasal PolyposisGermany, Belgium
-
Fondation Ophtalmologique Adolphe de RothschildCompletedChronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
-
Optinose US Inc.CompletedBilateral Nasal PolyposisUnited States, Canada
-
Central Hospital, Nancy, FranceUnknown
-
Université de SherbrookeTerminatedChronic Rhinosinusitis (Diagnosis), Nasal PolyposisCanada
-
Optinose US Inc.RecruitingBilateral Nasal PolyposisUnited States
-
Keymed Biosciences Co.LtdNot yet recruitingChronic Rhinosinusitis With Nasal Polyposis
-
Regeneron PharmaceuticalsSanofiRecruitingChronic Rhinosinusitis With Nasal PolyposisUnited States, Italy, Canada, Japan, Germany, Netherlands
-
AstraZenecaActive, not recruitingNasal PolyposisUnited States, Italy, Belgium, Taiwan, Thailand, Vietnam, France, Hungary, China, Japan, Australia, Argentina, Poland, Russian Federation, Turkey, Bulgaria, Chile
Clinical Trials on Fluticasone Propionate
-
University of FloridaFood and Drug Administration (FDA)Completed
-
GlaxoSmithKlineCompleted
-
Teva Pharmaceuticals USATerminatedSeasonal Allergic RhinitisUnited States
-
PfizerCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Philippines, Canada, Brazil
-
Padagis LLCCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
Boehringer IngelheimCompletedAsthmaUnited States, Australia, Canada, Colombia, Korea, Republic of, Mexico, New Zealand, Peru, Philippines, Taiwan